Cadila Pharnmaceuticals
14
1
1
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
14.3%
2 terminated/withdrawn out of 14 trials
81.8%
-4.7% vs industry average
43%
6 trials in Phase 3/4
0%
0 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas
Role: collaborator
A Clinical Trial to Evaluate Efficacy and Safety of Two Different Formulations of Topical Calcipotriol in Patients With Mild to Moderate Plaque Psoriasis
Role: lead
The International Polycap Study 3 (TIPS-3)
Role: collaborator
Effect of CPL-2009-0031 in the Treatment of Patients With Uncontrolled Type 2 Diabetes Mellitus
Role: lead
Study of Mycobacterium w in Superficial Transitional Cell Carcinoma of Bladder
Role: lead
A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients
Role: lead
Clinical Trial of Mycobacterium w in COVID-19 Positive Patients, Hospitalized But Not Critically Ill
Role: lead
Clinical Trial to Evaluate Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19
Role: lead
A Study of Mycobacterium w in Combination With Paclitaxel Plus Cisplatin in Advanced Non Small Cell Lung Cancer
Role: lead
Study of Mycobacterium w in BCG Refractory Superficial Transitional Cell Carcinoma of Bladder
Role: lead
A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer
Role: lead
The Indian POLYCAP Study (TIPS)
Role: collaborator
Safety Study of CADI-05 in Patients With Advanced Stage Melanoma
Role: lead
Efficacy & Safety Study of Recombinant Human Erythropoietin -Alpha, in Patients With Anemia of Chronic Renal Failure
Role: lead
All 14 trials loaded